MedTrace Logo

Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer

NCT07490119 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2026-03-24

No results posted yet for this study

Summary

This is a single-arm, single-center, exploratory study aimed at exploring the treatment of RAS wild-type recurrent/metastatic colorectal cancer with the combination of becotatug vedotin and cetuximab as a salvage therapy

Conditions

  • RAS Wild Type mCRC

Interventions

DRUG

Becotatug Vedotin

On the first day of every 3 weeks, Becotatug Vedotin will be administered via intravenous infusion at 2.0 mg/kg.

DRUG

Cetuximab

On the first day of every 2 weeks, Cetuximab will be administered via intravenous infusion at 500mg/m2

Sponsors & Collaborators

  • Shanghai Cancer Hospital, China

    collaborator OTHER

  • Fudan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2028-06-01
Completion
2029-06-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07490119 on ClinicalTrials.gov